For almost a decade, Momentum has been offering clients a wide range of early drug discovery services including high-throughput screening, hit characteriza...
SBI-100 Ophthalmic Emulsion, a CB1 agonist/activator delivered as a topical eye drop, was developed to treat patients with elevated intraocular pressure ...
- Collaboration leverages expertise in artificial intelligence from Genentech and NVIDIA to unlock scientific innovation and empower R&D at a sca...
GBM AGILE Adaptive Platform Trial Recruiting in Australia Austin Health in Melbourne and Royal North Shore Hospital in Sydney are Now Enrolling Patients ...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...
Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease bioma...
Seven major research projects to receive more than £14 million to develop new tests, treatments and devices for neurodegenerative diseases includin...
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with Uli...
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research coll...
The assembly of the chromosomes, and a set of related biological insights, are among the findings published online November 8 in 10 papers in the journals ...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as ea...
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
© 2023 Biopharma Boardroom. All Rights Reserved.
